- AU$310.77m
- AU$276.48m
- AU$3.42m
Australia's Race Oncology jumps on improved drug formulation
Brief: Race Oncology Posts FY Loss Attributable A$11.2 Million
Australia's Race Oncology jumps on encouraging results from cancer drug trial
Brief: Race Oncology Says Zantrene Shows Synergy With BRAF & MEK Inhibitors In Treating Melanoma
Australia's Race Oncology rises on announcing share buyback
Brief: Race Oncology Says It Approved On-Market Share Buyback For Up To 4 Mln Shares
Brief: Race Oncology Seeks Trading Halt Pending Announcement On Clinical Results For Dose Escalation Phase Of 1B/2 Zantrene Aml Trial In Israel
Brief: Race Oncology Gets Receives Governance Approval For AML EMD & MDS Trial
Brief: Race Oncology Says Signed Clinical Trial Collaboration And Supply Deal With Astex Pharmaceuticals
Australia Stock Exchange release from RACE ONCOLOGY LT : PRE_NR Ends: 09:20:49
Australia Stock Exchange release from RACE ONCOLOGY LT : Zantrene highly effective in EMD AML Mouse Model
Australia Stock Exchange release from RACE ONCOLOGY LT : Race ASX Small and Mid-Cap Conference Presentation
Australia Stock Exchange release from RACE ONCOLOGY LT : Compelling Zantrene Preclinical Kidney Cancer Data
Australia Stock Exchange release from RACE ONCOLOGY LT : PRE_NR Ends: 09:37:31
Australia Stock Exchange release from RACE ONCOLOGY LT : Cleansing Notice
Australia Stock Exchange release from RACE ONCOLOGY LT : Application for quotation of securities - RAC
Australia Stock Exchange release from RACE ONCOLOGY LT : Appendix 3Y - Dr Daniel Tillett
Australia Stock Exchange release from RACE ONCOLOGY LT : Appendix 4D & Half-Year Financial Statements
Australia Stock Exchange release from RACE ONCOLOGY LT : PRE_NR Ends: 14:07:18